论文部分内容阅读
原发性硬化性胆管炎(PSC)是以进行性胆汁淤积并继发胆汁性肝硬化为特征的肝脏慢性炎症性疾病,属自身免疫性疾病。迄今尚无广泛肯定疗法。本文作者用FK 506(系分离于链球菌属tsukubaenis,其免疫抑制活性是环孢素10～100倍,属大环内酯类抗生素,已广泛用于脏器移植病人)治疗10例PSC患者,用自身对照开放试验观察该药治疗PSC的有效性及毒性作用。 方法:10例PSC患者,每例用药前均作血常规及血小板计数、肝功能、ERCP或PTHC、
Primary sclerosing cholangitis (PSC) is a chronic inflammatory disease of the liver characterized by progressive cholestasis secondary to biliary cirrhosis and is an autoimmune disease. To date, there is no widespread affirmation of therapies. In this study, 10 patients with PSC were treated with FK 506 (isolated from Streptococcus tsukubaenis, whose immunosuppressive activity was 10-100 times higher than that of cyclosporine and a macrolide antibiotic which has been widely used in organ transplant) The self-controlled open trial was used to observe the effectiveness and toxicity of the drug in the treatment of PSC. Methods: 10 cases of PSC patients before treatment were used for blood and platelet count, liver function, ERCP or PTHC,